Kintara Therapeutics (KTRA) said Wednesday its board has approved a 1-for-35 reverse stock split of its shares.
The stock will begin trading on a post-split basis on the Nasdaq Capital Market under the new name, TuHURA Biosciences, and under the "HURA" ticker on Thursday. The rebranding follows the anticipated close of its merger with TuHURA Biosciences, Kintara said.
The reverse stock split will reduce Kintara shares to about 1.6 million from around 55.6 million shares, the firm said.
Kintara shares fell more than 7% in recent trading.
Price: 0.21, Change: -0.02, Percent Change: -7.93
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments